Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders

Preeclampsia

Preeclampsia is a disease of pregnancy that occurs after the 20th week of gestation. It is characterized by hypertension and proteinuria and it can develop into a life threatening eclampsia. The cause sometimes can be found in hereditary factors and complement dysregulation.

Systematic

Hypertension
ACE
ACE2
AGT
Benign hyperproreninemia
Monogenic hypertension
Preeclampsia
APOL1
Preeclampsia 1
Preeclampsia 2
Preeclampsia 3
Preeclampsia 4
STOX1
Preeclampsia 5
CORIN
Salt-sensitive essential hypertension
VEGFC

References:

1.

Hillermann R et. al. (2005) The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia.

[^]
2.

Wallukat G et. al. (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.

[^]
3.

Reidy KJ et. al. (2018) Fetal-Not Maternal-APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry.

[^]
4.

Pan J et. al. (2002) Genomic structures of the human and murine corin genes and functional GATA elements in their promoters.

[^]
5.

Knappe S et. al. (2003) Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin.

[^]
6.

Dries DL et. al. (2005) Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension.

[^]
7.

Guipponi M et. al. (2008) An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss.

[^]
8.

Wang W et. al. (2008) Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity.

[^]
9.

Cui Y et. al. (2012) Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy.

[^]
10.

Dong N et. al. (2013) Corin mutation R539C from hypertensive patients impairs zymogen activation and generates an inactive alternative ectodomain fragment.

[^]
11.

Dong N et. al. (2014) Corin mutations K317E and S472G from preeclamptic patients alter zymogen activation and cell surface targeting. [Corrected].

[^]
12.

Laivuori H et. al. (2003) Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families.

[^]
13.

Chesley LC et. al. (1968) The familial factor in toxemia of pregnancy.

[^]
14.

None (1980) Genetic control of pre-eclampsia.

[^]
15.

Fisher KA et. al. (1981) Hypertension in pregnancy: clinical-pathological correlations and remote prognosis.

[^]
16.

Van Meter TD et. al. (1993) Concerns about the genetics of pre-eclampsia.

[^]
17.

Brenner B et. al. (1996) HELLP syndrome associated with factor V R506Q mutation.

[^]
18.

Harrison GA et. al. (1997) A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q.

[^]
19.

Sohda S et. al. (1997) Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia.

[^]
20.

Arngrímsson R et. al. (1997) Evidence for a familial pregnancy-induced hypertension locus in the eNOS-gene region.

[^]
21.

Lindqvist PG et. al. (1998) Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss--a possible evolutionary selection mechanism.

[^]
22.

Kupferminc MJ et. al. (1999) Increased frequency of genetic thrombophilia in women with complications of pregnancy.

[^]
23.

Thornton JG et. al. (1999) Twin mothers, pregnancy hypertension and pre-eclampsia.

[^]
24.

Arngrímsson R et. al. (1999) A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13.

[^]
25.

Zusterzeel PL et. al. (1999) Glutathione S-transferase isoenzymes in decidua and placenta of preeclamptic pregnancies.

[^]
26.

Rajkovic A et. al. (2000) Methylenetetrahydrofolate reductase 677 C --> T polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe.

[^]
27.

Napolitano M et. al. (2000) Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas.

[^]
28.

Page NM et. al. (2000) Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia.

[^]
29.

Brown MA et. al. (2000) The detection, investigation and management of hypertension in pregnancy: full consensus statement.

[^]
30.

Moses EK et. al. (2000) A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2.

[^]
31.

Roberts JM et. al. (2001) Pathogenesis and genetics of pre-eclampsia.

[^]
32.

Esplin MS et. al. (2001) Paternal and maternal components of the predisposition to preeclampsia.

[^]
33.

Zusterzeel PL et. al. (2001) A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia.

[^]
34.

Lachmeijer AM et. al. (2001) A genome-wide scan for preeclampsia in the Netherlands.

[^]
35.

Zusterzeel PL et. al. (2002) Paternal contribution to the risk for pre-eclampsia.

[^]
36.

Laasanen J et. al. (2002) Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia.

[^]
37.

Maynard SE et. al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

[^]
38.

None (2003) The genetics of pre-eclampsia: a feto-placental or maternal problem?

[^]
39.

Faisel F et. al. (2004) Susceptibility to pre-eclampsia in Finnish women is associated with R485K polymorphism in the factor V gene, not with Leiden mutation.

[^]
40.

Levine RJ et. al. (2004) Circulating angiogenic factors and the risk of preeclampsia.

[^]
41.

Cnattingius S et. al. (2004) Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study.

[^]
42.

Hiby SE et. al. (2004) Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.

[^]
43.

None (2005) Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study.

[^]
44.

Uz E et. al. (2007) Extremely skewed X-chromosome inactivation is increased in pre-eclampsia.

[^]
45.

Kanasaki K et. al. (2008) Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia.

[^]
46.

Berends AL et. al. (2008) Familial aggregation of preeclampsia and intrauterine growth restriction in a genetically isolated population in The Netherlands.

[^]
47.

Zhou CC et. al. (2008) Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice.

[^]
48.

Payne B et. al. (2011) Assessment, surveillance and prognosis in pre-eclampsia.

[^]
49.

Uzan J et. al. (2011) Pre-eclampsia: pathophysiology, diagnosis, and management.

[^]
50.

van Dijk M et. al. (2012) HELLP babies link a novel lincRNA to the trophoblast cell cycle.

[^]
51.

Oudejans CB et. al. (2015) Susceptibility allele-specific loss of miR-1324-mediated silencing of the INO80B chromatin-assembly complex gene in pre-eclampsia.

[^]
Update: Sept. 26, 2018